

1 **Lack of effectiveness of Bebtelovimab Monoclonal Antibody Among High-Risk**
2 **Patients with SARS-Cov-2 Omicron During BA.2, BA.2.12.1 and BA.5 Subvariants**
3 **Dominated Era**

4
5 Srilekha Sridhara, MD^{1*}, Ahmet B. Gungor, MS^{2*}, Halil K. Erol, MD¹, Mohanad Al-Obaidi, MD, MPH³
6 Tirdad T. Zangeneh, DO, MA, FACP, FIDSA, FAST³, Edward J. Bedrick, PhD⁴, Venkatesh K. Ariyamuthu, MD¹,
7 Aneesha Shetty, MD¹, Abd A. Qannus, MD¹, Katherine Mendoza, MPH¹, Sangeetha Murugapandian, MD¹,
8 Gaurav Gupta, MD⁵, Bekir Tanriover, MD, MPH, MBA, FAST¹

9 *Equally contributed as the first author

10

11 **Affiliations:**

12 ¹Division of Nephrology, College of Medicine, The University of Arizona, Tucson, Arizona, U.S.A.

13 ²Division of Nephrology, The Banner University Medical Center, Tucson, Arizona, U.S.A.

14 ³Division of Infectious Diseases, College of Medicine, The University of Arizona, Tucson, Arizona, U.S.A.

15 ⁴Department of Epidemiology and Biostatistics, College of Public Health, The University of Arizona,
16 Tucson, Arizona, U.S.A.

17 ⁵Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, U.S.A.

18

19 **Correspondence:**

20 Bekir Tanriover, MD, MPH, MBA, FAST

21 Division of Nephrology, College of Medicine, The University of Arizona, Tucson, Arizona

22 1501 N Campbell Avenue PO Box 245022 Tucson, AZ 85724, U.S.A.

23 Phone: 520-626-0978 Fax: 520-626-2024

24 btanriover@arizona.edu

25 **ABSTRACT:**

26 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants are expected to be
27 resistant to Bebtelovimab (BEB) monoclonal antibody (MAb) and the real-world experience regarding its
28 effectiveness is scarce. This retrospective cohort study reports a data analysis in Banner Healthcare
29 System (a large not-for-profit organization) between 4/5/2022 and 8/1/2022 and included 19,778
30 Coronavirus disease-19 (COVID-19) positive (by PCR or direct antigen testing) patients who were selected
31 from Cerner-Electronic Health Record after the exclusions criteria were met. The study index date for
32 cohort was determined as the date of BEB MAb administration or the date of the first positive COVID-19
33 testing. The cohort consist of COVID-19 infected patients who received BEB MAb (N=1,091) compared to
34 propensity score (PS) matched control (N=1,091). The primary outcome was the incidence of 30-day all-
35 cause hospitalization and/or mortality. All statistical analyses were conducted on the paired (matched)
36 dataset. For the primary outcome, the event counts and percentages were reported. Ninety-five percent
37 Clopper-Pearson confidence intervals for percentages were computed. The study cohorts were 1:1
38 propensity matched without replacement across 26 covariates using an optimal matching algorithm that
39 minimizes the sum of absolute pairwise distance across the matched sample after fitting and using logistic
40 regression as the distance function. The pairs were matched exactly on patient vaccination status, BMI
41 group, age group and diabetes status. Compared to the PS matched control group (2.6%; 95% confidence
42 interval [CI]: 1.7%, 3.7%), BEB MAb use (2.2%; 95% CI: 1.4%, 3.3%) did not significantly reduce the
43 incidence of the primary outcome ($p=0.67$). In the subgroup analysis, we observed similar no-difference
44 trends regarding the primary outcomes for the propensity rematched BEB MAb treated and untreated
45 groups, stratified by patient vaccination status, age (<65 years or ≥ 65), and immunocompromised status
46 (patients with HIV/AIDS or solid organ transplants or malignancy including lymphoproliferative disorder).
47 The number needed to treat (1/0.026-0.022) with BEB MAb was 250 to avoid one hospitalization and/or

48 death over 30 days. The BEB MAb use lacked efficacy in patients with SARS-CoV-2 Omicron subvariants
49 (mainly BA.2, BA.2.12.1, and BA.5) in the Banner Healthcare System in the Southwestern United States.

50 **INTRODUCTION:**

51 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve into new variants of
52 concern (VOC) characterized by mainly spike receptor binding domain mutations, which are the target of
53 authorized neutralizing monoclonal antibodies (MAb) to reduce hospitalization and death.(1) The spike
54 protein mutations of SARS-CoV-2 Omicron subvariants have reduced susceptibility to earlier authorized
55 MAbs (e.g. bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab) for outpatient treatment
56 of coronavirus disease-19 (COVID-19).(1-5) Based on invitro and limited clinical data(6), the Food and Drug
57 Administration (FDA) granted Emergency Use Authorization (EUA) for LY-CoV1404 (Bebtelovimab [BEB])
58 on February 11, 2022, as an alternative therapy for high-risk patients with mild to moderate COVID-19.(4)
59 BEB is an alternative treatment option for patients who are unable to receive remdesivir 3-days IV
60 treatment due to logistic challenges or have contraindications for the use of nirmaltrevir/ritonavir due to
61 severe drug-drug interactions. Bebtelovimab was recommended based on laboratory results indicating
62 potent activity against the Omicron VOC and other VOCs based on data from the Phase 2 BLAZE-4 study.(4,
63 6) However, there is still no phase 3 clinical trial data to support BEB's use and real-world experience is
64 limited in the Omicron subvariants dominated era.(7, 8)

65 In this study, we assessed the composite outcome (all-cause hospitalization and/or death over 30-day) in
66 high-risk outpatients, who received BEB MAb compared to the propensity score (PS) matched untreated
67 control group for COVID-19 in the Banner Healthcare System (a large not-for-profit organization) in the
68 Southwestern United States, during a period (4/5/2022-8/1/2022) dominated by SARS-CoV-2 Omicron
69 BA.2, BA.2.12.1, and BA.5 subvariants.(9)

70 **METHODS:**

72 ***Patient Consent Statement***

73 This study was approved by the Institutional Review Board of the University of Arizona with a waiver of
74 patient consent given the retrospective nature of the study. The study adhered to the Strengthening the
75 Reporting of Observational Studies in Epidemiology (STROBE) statement (See Supplemental Document).

76 ***Overview***

77 This observational retrospective cohort study of positive COVID-19 patients was conducted between April
78 5, 2022, and August 1, 2022. Patients' follow-up date was censored on August 31, 2022. All data pertaining
79 to BEB MAb treated patients and untreated patients were captured from electronic health records (Cerner
80 EHR) in the Banner Health Care System, which houses thirty hospitals and several clinics across the
81 Southwestern United States, mainly in Arizona. A multidisciplinary team formed under the Banner Health
82 Care System Monoclonal Antibody Treatment program reviews patients' eligibility for antiviral therapy
83 (remdesivir and nirmatrelvir-ritonavir as the first line agents) and an alternative MAb treatment, guided
84 by the FDA EUA.(10) The alternative BEB MAb therapy (175 mg administered as a single intravenous
85 injection over 30 seconds) is indicated for mild-to-moderate severe SARS-CoV-2 infection (within 7 days
86 of symptom onset) in adults who are at high-risk for progression to severe disease and in children older
87 than 12 years-old and weighing 40 kg or above.

88 In this study, 19,778 COVID-19 positive (by PCR or direct antigen testing) patients were selected from
89 Cerner-EHR after exclusions were made (Figure 1). During the study period, there were 12 MAB infusion
90 sites (for the treatment cohort) and 128 testing sites in the Banner Health Care System. The study index
91 date for cohorts was determined as the date of BEB MAb administration or the date of the first positive
92 COVID-19 testing. Patients were excluded if they were younger than 18 years of age, in hospice care,
93 received BEB MAb in the inpatient setting, received tixagevimab-cilgavimab prophylactic MAb (Evusheld)
94 within last 3 months/ nirmatrelvir-ritonavir (Paxlovid) within 15 days/ molnupiravir (Lagevrio) within 15

95 days of index date, or weighted less than 40 kilograms. The resulting pre-propensity matched study cohort
96 comprised 1,099 BEB MAb treated patients and 18,679 untreated patients. Demographic and clinical
97 covariates of both cohorts were extracted from the EHR. Clinical covariates were derived from the
98 Charlson Comorbidity Index codes (based on International Classification of Diseases, Tenth Revision [ICD-
99 10] codes documented in the EHR within five years preceding the patient index date). The post-propensity
100 match cohort consisted of 1,091 pairs (N =2,182 patients).

101 *Figure 1. Study cohort selection.*

102 **Outcome**

103 The primary outcome was the incidence of all-cause hospitalization and/or mortality (the composite
104 outcome) at 30-days of the index date in the post-propensity matched cohort.

105 **Statistical Methods**

106 All statistical analyses were conducted on the paired (matched) dataset. For the primary outcome, the
107 event count and percentage of the event was reported. Ninety-five percent Clopper-Pearson confidence
108 intervals for percentages were computed in the R package Exactci. The study cohorts were 1:1
109 propensity matched without replacement across 26 covariates using an optimal matching algorithm that
110 minimizes the sum of absolute pairwise distance across the matched sample after fitting and using
111 logistic regression as the distance function. The pairs were matched exactly on patient vaccination
112 status, BMI group, age group and diabetes status. Patients were classified as fully vaccinated if they had
113 at least two or three (depending on immunocompromised status) COVID-19 mRNA technology vaccine
114 (Pfizer or Moderna) reported in the EHR. The vaccination status of Arizona residents is available through
115 a web-portal (the Arizona State Immunization Information System).(11)

116 The covariate balance was assessed by comparing pre- and post-match standardized mean differences
117 (SMDs). MatchIt package from the statistical computing software R was used to build the propensity
118 models. For each outcome, event count, percentage with the event and ninety-five percent confidence
119 intervals have been reported. Exact McNemar's test was used to compare the proportions in the pair
120 dataset and the 95% confidence intervals for proportions were calculated. P-values <0.05 was
121 considered statistically significant. The matched sets were constructed for the subgroup analysis and the
122 incidence of the composite outcome was reported for the subgroups stratified by vaccination status
123 (fully vaccinated and not fully vaccinated), age groups (age <65 and age ≥65), and immunocompromised
124 status (patients with comorbidities including HIV/AIDS, malignancy and solid organ transplantation, and
125 patients without these comorbidities). The Kaplan-Meier estimator was used to plot curves for the
126 composite outcome between the post-PS matched groups during the study period. We fitted a
127 multivariable Cox proportional hazard regression model predicting the composite outcome in the PS
128 matched group.

129 **RESULTS:**

130 ***Patient Characteristics***

131 Table 1 shows the characteristics of BEB MAb and untreated control cohorts before and after propensity
132 matching. All post-propensity matching covariate SMDs were < 0.1 threshold, indicating an optimal
133 matching. In the post propensity matched cohort, the median age of patients in the BEB MAb treatment
134 group was 64 (interquartile range [IQR], 50-74) years; 43% were male, and 78.7% were White race and
135 68.6% patients were fully vaccinated. Some of the high-risk characteristics included age ≥60 years
136 (58.7%), hypertension [52.5%], diabetes mellitus (31.7%), chronic pulmonary disease (31.4%), BMI ≥35
137 kg/m² (27.3%), chronic kidney disease—any stage (16.9%), chronic liver disease (13.8%), human
138 immunodeficiency virus infection (HIV/AIDS) and/or opportunistic infections (11%), heart failure (8.3%),

139 malignancy including lymphoproliferative disease (7.7%), and solid organ transplant and hematopoietic
 140 stem cell transplants (4.9%).

141

142 Table 1: Patient characteristics and covariate balance before and after propensity matching.

	After Propensity Matching			Before Propensity Matching		
	BEB Treatment Cohort	Untreated Control Cohort	SMD	BEB Treatment Cohort	Untreated Control Cohort	SMD
	N=1,091	N=1,091		N=1,099	N=18,679	
Age	64.0 [50.0,74.0]	64.0 [50.0,74.0]		64.0 [50.0,74.0]	46.0 [32.0,63.0]	
Age Groups						
18-35	82 (7.5)	82 (7.5)	0.00	83 (7.6)	5,969 (32.0)	-0.92
35-50	200 (18.3)	200 (18.3)	0.00	202 (18.4)	4,568 (24.5)	0.16
50-60	168 (15.4)	168 (15.4)	0.00	169 (15.4)	2,849 (15.3)	0.00
60-70	275 (25.2)	275 (25.2)	0.00	275 (25.0)	2,539 (13.6)	0.26
>70	366 (33.5)	366 (33.5)	0.00	370 (33.7)	2,754 (14.7)	0.40
Sex						
Male	469 (43.0)	474 (43.4)	-0.01	474 (43.1)	7,366 (39.4)	0.07
Fully Vaccinated						
Yes	748 (68.6)	748 (68.6)	0.00	752 (68.4)	7,430 (39.8)	0.62
No	298 (27.3)	298 (27.3)	0.00	301 (27.4)	5,538 (29.6)	-0.05
Unknown	45 (4.1)	45 (4.1)	0.00	46 (4.2)	5,711 (30.6)	-1.32
Race/Ethnicity						
White	859 (78.7)	866 (79.4)	-0.02	867 (78.9)	11,801 (63.2)	0.39
Black	48 (4.4)	44 (4.0)	0.02	48 (4.4)	1,058 (5.7)	-0.06
Hispanic	120 (11.0)	109 (10.0)	0.03	120 (10.9)	3,542 (19.0)	-0.26
Asian/Pacific Islander	13 (1.2)	16 (1.5)	-0.03	13 (1.2)	360 (1.9)	-0.07
Native American/Alaskan	8 (0.7)	9 (0.8)	-0.01	8 (0.7)	228 (1.2)	-0.06
Unknown	43 (3.9)	47 (4.3)	-0.02	43 (3.9)	1,690 (9.0)	-0.26
BMI Group						
≤20	24 (2.2)	24 (2.2)	0.00	26 (2.4)	811 (4.3)	-0.13
20-25	164 (15.0)	164 (15.0)	0.00	166 (15.1)	4,005 (21.4)	-0.18
25-30	305 (28.0)	305 (28.0)	0.00	307 (27.9)	4,968 (26.6)	0.03
30-35	236 (21.6)	236 (21.6)	0.00	236 (21.5)	3,477 (18.6)	0.07
35-40	160 (14.7)	160 (14.7)	0.00	161 (14.6)	1,844 (9.9)	0.14
>40	137 (12.6)	137 (12.6)	0.00	137 (12.5)	1,545 (8.3)	0.13
Unknown	165 (6.0)	65 (6.0)	0.00	66 (6.0)	2,029 (10.9)	-0.20
Time period						
4/05-30/2022	103 (9.4)	131 (12.0)	-0.09	103 (9.4)	1,213 (6.5)	0.10
5/01-31/2022	249 (22.8)	268 (24.6)	0.00	252 (22.9)	3,652 (19.6)	0.08
6/01-30/2022	372 (34.1)	358 (32.8)	0.04	375 (34.1)	6,746 (36.1)	-0.04
7/01-31/2022	367 (33.6)	334 (30.6)	0.03	369 (33.6)	7,040 (37.7)	-0.09
8/01/2022	0 (0.0)	0 (0.0)	0.00	0 (0.0)	28 (0.1)	-0.04

143

144

145

146

147 (Table S1 continued)

	After Propensity Matching			Before Propensity Matching		
	BEB Treatment Cohort	Untreated Control Cohort	SMD	BEB Treatment Cohort	Untreated Control Cohort	SMD
	N=1,091	N=1,091		N=1,099	N=18,679	
Myocardial Infarction	64 (5.9)	47 (4.3)	0.06	65 (5.9)	526 (2.8)	0.13
Heart Failure	91 (8.3)	73 (6.7)	0.06	93 (8.5)	797 (4.3)	0.15
Cerebrovascular Disease	93 (8.5)	66 (6.0)	0.09	94 (8.6)	674 (3.6)	0.18
Hemiplegia or Paraplegia	12 (1.1)	11 (1.0)	0.01	12 (1.1)	161 (0.9)	0.02
Peripheral Vascular Disease	100 (9.2)	84 (7.7)	0.05	101 (9.2)	725 (3.9)	0.18
Chronic Pulmonary Disease	343 (31.4)	311 (28.5)	0.06	346 (31.5)	3,907 (20.9)	0.23
Dementia	21 (1.9)	19 (1.7)	0.01	21 (1.9)	237 (1.3)	0.05
Hypertension	573 (52.5)	534 (48.9)	0.07	580 (52.8)	5,199 (27.8)	0.50
Diabetes without Chronic Complications	242 (22.2)	242 (22.2)	0.00	246 (22.4)	2,236 (12.0)	0.25
Diabetes with Chronic Complications	104 (9.5)	104 (9.5)	0.00	110 (10.0)	838 (4.5)	0.18
Renal Mild-Moderate-Advanced Disease (CKD stage 1-4)	147 (13.5)	118 (10.8)	0.08	153 (13.9)	780 (4.2)	0.28
Renal Severe Disease (CKD stage 5 and ESRD)	37 (3.4)	21 (1.9)	0.08	39 (3.5)	201 (1.1)	0.13
Mild Liver Disease	117 (10.7)	95 (8.7)	0.07	117 (10.6)	1,034 (5.5)	0.17
Moderate to Severe Liver Disease	34 (3.1)	18 (1.6)	0.08	35 (3.2)	185 (1.0)	0.13
Peptic Ulcer Disease	26 (2.4)	18 (1.6)	0.05	26 (2.4)	224 (1.2)	0.08
Rheumatic Disease	60 (5.5)	57 (5.2)	0.01	60 (5.5)	466 (2.5)	0.13
Malignancy, skin cancers and lymphoproliferative disorders	84 (7.7)	72 (6.6)	0.04	84 (7.6)	645 (3.5)	0.16
Metastatic Solid Tumor	25 (2.3)	25 (2.3)	0.00	25 (2.3)	148 (0.8)	0.10
HIV/AIDS/Opportunistic Infections	120 (11.0)	94 (8.6)	0.08	123 (11.2)	1,425 (7.6)	0.11
Solid Organ Transplant	53 (4.9)	31 (2.8)	0.09	56 (5.1)	150 (0.8)	0.20

148

149 Data are presented as mean [SD] for continuous measures, and n (%) for categorical measures.

150 Abbreviations: MAb= monoclonal antibody; SMD= standardized mean difference; IQR= interquartile range; BMI= body mass index; CKD=

151 chronic kidney disease; ESRD= end-stage renal disease; HIV= Human Immunodeficiency Virus; AIDS= acquired immunodeficiency syndrome.

152

153 **Outcomes**

154 The incidence of the composite outcome in the pre-PS matched untreated control cohort was 1.8%

155 (data not shown). Table 2 shows the result of the composite outcome within 30 days in the post

156 propensity matched cohorts. Compared to the untreated control group, the incidence of patients with
 157 the composite outcome in the BEB MAb treated group within 30 days is 2.2% (95% CI 1.4% to 3.3%) vs.
 158 2.6% (95% CI: 1.7% to 3.7%) (P-value =0.67). The all-cause hospitalizations within 30 days in the BEB
 159 MAb cohort was 2.2% (95% CI: 1.4% to 3.3%) vs 2.5% (95% CI, 1.6% to 3.6%) (P value =0.77); the
 160 proportion of patients with all-cause mortality within 30 days was 0% (95% CI, 0% to 0%) vs 0.3% (95%
 161 CI, 0.1% to 0.8%; P-value =0.25). Figure 2 showed no difference between the Kaplan Meier curves for the
 162 composite outcome stratified by BEB MAb treatment status at last follow-up (P-value =0.27). The
 163 number needed to treat (1/0.026-0.022) with BEB MAb was 250 to avoid one hospitalization and/or
 164 death over 30 days.

165 *Table 2. The primary composite outcome between the propensity matched Bebtelovimab (BEB)*
 166 *monoclonal antibody (MAb) and untreated control groups.*

Primary outcomes in post-propensity score-matched cohorts						
	BEB MAb Treatment Group		Untreated Control Group		Difference in % with 95% CI**	P-value
	N (%)	95% CI*	N (%)	95% CI*		
Composite outcome within 30 days						
Whole cohort	24 (2.2)	1.4, 3.3	28 (2.6)	1.7, 3.7	-0.4 (-1.7, 1.0)	0.67
All-cause hospitalization within 30 days						
Whole cohort	24 (2.2)	1.4, 3.3	27 (2.5)	1.6, 3.6	-0.3 (-1.6, 1.1)	0.77
Mortality within 30 days						
Whole cohort	0 (0.0)	0.0, 0.3	3 (0.3)	0.1, 0.8	-0.3 (-0.8, 0.1)	0.25

167 Abbreviations: BEB= Bebtelovimab; MAb= monoclonal antibody; CI= Confidence Interval.

168 * The Clopper-Pearson method was used to calculate 95% confidence intervals for the outcome percentages using the R package (Exactci).

169 ** CI for difference in paired proportions between the treatment and control cohorts.

170

171 *Figure 2. Kaplan Meier curves for the composite outcome in patients who received Bebtelovimab*
 172 *monoclonal antibody treated group vs. not-treated control group between April 5, 2022, and August 1,*
 173 *2022.*

174

175 In the subgroup analysis, we observed similar no-difference trends regarding the primary outcomes for
 176 the propensity rematched BEB MAb treated and untreated groups, stratified by patient vaccination
 177 status, age (<65 years or ≥65), and immunocompromised status (patients with HIV/AIDS or solid organ
 178 transplants or malignancy including lymphoproliferative disorder), see Table 3 below.

179 *Table 3: Subgroup analysis for the primary composite outcome stratified by patient vaccination status*
 180 *(fully vaccinated vs. not fully vaccinated), age category (age <65 vs. age ≥65), and immunocompromised*
 181 *status (comorbidities including HIV/AIDS or solid organ transplants or malignancy) between the*
 182 *propensity matched Bebtelovimab (BEB) and untreated control groups.*
 183

Primary outcome in the post-propensity-matched study cohort with subgroups						
	BEB MAb Treatment Group		Untreated Control Group		Difference in % with 95% CI***	P-value
	N (%)	95% CI*	N (%)	95% CI**		
Fully vaccinated* N=1,496	7 (0.9)	0.4, 1.9	11 (1.5)	0.7, 2.6	-0.5 (-1.8, 0.7)	0.48
Not fully vaccinated N=596	17 (5.7)	3.4, 9.0	17 (5.7)	3.4, 9.0	0.0 (-4.0, 4.0)	1.00
Immunocompromised N=250	9 (7.2)	3.3, 13.2	11 (8.8)	4.5, 15.2	-1.6 (-9.2, 6.0)	0.81
Not- Immunocompromised N=1,636	10 (1.2)	0.6, 2.2	7 (0.9)	0.3, 1.8	0.4 (-0.8, 1.5)	0.63
Age ≥65 N=1,014	13 (2.6)	1.4, 4.3	17 (3.4)	2.0, 5.3	-0.8 (-3.1, 1.5)	0.57
Age <65 N=1,068	8 (1.5)	0.6, 2.9	9 (1.7)	0.8, 3.2	-0.2 (-2.0, 1.6)	1.00

184 Abbreviations: HIV= human immunodeficiency virus; AIDS= acquired immunodeficiency syndrome; Bebtelovimab= BEB; MAb= monoclonal
 185 antibody; CI= Confidence Interval.

186 *This analysis included the patients with known vaccination status only.

187 **The Clopper-Pearson method was used to calculate 95% confidence intervals (CI) for the outcome percentages using the R package (Exactci).

188 *** CI for difference in paired proportions between the BEB MAb treatment and control cohorts.
 189

190 **Hazard model for Composite Outcome among the Propensity Matched SARS-Cov-2 Infected Patients**

191 Table 4 shows the multivariable Cox proportional hazards model, (accounted for the paired data)

192 predicting hazards for the composite outcome among the post-PS patients. The BEB MAb use was not

193 associated with statistically significant lower hazards of composite outcome (hazard ratio [HR] 0.75; 95%

194 CI: 0.43 to 1.31, P-value =0.31). However, fully vaccinated status continued to be protective while age
 195 >65 and immunosuppressed status increased the hazards for primary outcome two to four folds,
 196 respectively.

197 *Table 4. Multivariable Cox proportional hazard model* for the composite outcome among the post-*
 198 *propensity matched COVID-19 infected patients in the Banner Healthcare System between April 5, 2022,*
 199 *and August 1, 2022.*

200

	Hazard Ratio (95% Confidence Interval)	Standard Error	P-value
Bebtelovimab monoclonal antibody use (yes vs. no)	0.75 (0.43-1.31)	0.21	0.31
Fully vaccinated status (Yes vs. no)	0.23 (0.12-.42)	0.07	<0.001
Age (≥65 vs. <65)	2.07 (1.15-3.74)	2.41	0.02
Immunocompromised** (Yes vs. no)	4.60 (2.58-8.19)	5.19	<0.001

201 *Accounted for the paired data.

202 **Immunocompromised status (the patients with HIV/AIDS or solid organ transplants or malignancy
 203 including lymphoproliferative disorder).

204

205 **DISCUSSION:**

206 In this retrospective propensity matched analysis, the incidence of the composite outcome was low
 207 (2.2%-2.6%) and treatment with the BEB MAb lacked efficacy against SARS-CoV-2 Omicron during an era
 208 dominated by BA.2, BA.2.12.1, and BA.5 subvariants to reduce the all-cause hospitalization and
 209 mortality over 30 days in Banner Health Care System in the Southwestern United States. Moreover, in
 210 the subgroup analysis for the composite outcome stratified by patient vaccination status, age category,
 211 and immunocompromised status between the PS matched groups, BEB MAb use failed to show
 212 significant efficacy. The hazards for the composite outcome were lower in the BEB MAb group but not
 213 statistically significant. However, fully vaccinated status continued to be protective while age >65 and

214 immunosuppressed status increased the hazards for primary outcome two to four folds, respectively.
215 Similar finding from epidemiological study showing possible protective immunity from previous
216 infections and vaccinations, and that older age can result in worse outcomes during the Omicron
217 wave.(12) Such findings can help stratifying risk groups when administering COVID-19 therapeutics.

218 The only published (non-peer-reviewed data) on the efficacy of BEB MAb comes from the Phase II Blaze
219 4 clinical trial during the period of alpha and delta waves, which showed that the incidence of the
220 primary outcome (hospitalization or death over 29 days) in the BEB MAb arm compared with the control
221 arm was similar, around 3%.(6) While in vitro studies showing preserved neutralization of SARS-COV2
222 variants (BA.2 and BA. 5), (13, 14) it was not demonstrated in clinical trials. Hence, the real-world
223 experience with BEB Mab use, especially during the periods of new variants emergence, is limited to a
224 couple of recently published studies in the general population(7, 8) and solid organ transplant
225 cohorts.(15, 16) A Mayo clinic study (N=2,833) reported that the BEB MAb use was associated with very
226 low incidence of the primary outcome (1.4%, 95% CI: 1.2% to 1.7%) between 3/20/2022 and 6/14/2022,
227 dominated by Omicron BA.2 subvariant.(8) However, the study was limited by a population of
228 predominantly White and fully vaccinated (>90%) patients, and moreover, the study lacked a matched
229 control group and did not clearly define exclusion criteria (e.g., tixagevimab-cilgavimab prophylactic
230 MAb (Evusheld) use etc.). Therefore, in the absence of control group comparison, it is difficult to
231 ascertain the author's conclusion of primary outcome of 1.4% because of the fully vaccinated status of
232 patients or the effect of the BEB MAb use. In contrast, our data suggest that the fully vaccinated patients
233 had similar primary outcome of 0.9% in BEB MAb group vs. 1.5% in non-treated PS matched group,
234 which signifies the importance of population immunity. In another study (N = 930 patients in each arm),
235 the University of Pittsburgh researchers showed that BEB MAb use, between 3/30/2022 and 5/30/2022,
236 significantly reduced 30-day hospitalization and/or death compared to the PS matched cohort, 3.1% vs.
237 5.5%, respectively.(7) But the protective effect was the most prominent among older,

238 immunosuppressed and fully vaccinated patients. The authors did not exclude the patients who
239 received tixagevimab-cilgavimab prophylactic MAb (Evusheld) and the cohort included small proportions
240 of racial minorities (Blacks/Hispanics/Asians) comprised approximately 4% of the final study cohort. The
241 SARS-Cov-2 Omicron BA.2 subvariant dominated the COVID-19 infections during that study period. In
242 terms of SOT recipients who received the BEB MAb, another study from the Mayo Clinic(16) reported
243 3.3% incidence of the primary outcome in their cohort (N=92) and a smaller number of SOT recipients
244 received BEB MAb compared to Sotrovimab MAb group. In contrast, the SOT recipients in our cohort
245 (n=53) had much higher incidence of hospitalization and death (9.4% in BEB MAb group vs. 6.5% in
246 control arm, P-value =0.64), data not shown. The differences in vaccination rates and the different
247 effects of Omicron subvariants may account for this variation.

248 On November 10, 2022, the NIH COVID-19 Treatment Guidelines Panel(17) reported that certain rapidly
249 increasing Omicron subvariants (e.g., BQ.1 and BQ.1.1) are likely to be resistant to BEB MAb(18) based
250 on in vitro neutralization studies.(19) The panel recommend BEB MAb only as an alternative treatment
251 for when preferred ritonavir-boosted nirmatrelvir or remdesivir are not available or contraindicated,
252 and when the majority of spreading (>50%) Omicron subvariants in a given region are susceptible, the
253 rating of evidence rated as level III (expert opinion). Later, on November 30, 2022, the U.S. Food & Drug
254 Administration removed the EUA of BEB due to the fact that a non-susceptible SARS-CoV-2 subvariants
255 account for majority of COVID 19 cases (Omicron BQ.1 and BQ.1.1 subvariants infections to be above
256 57% nationally).(20)

257 Large observational (real-life experiences) studies are necessary to show the efficacy assessment of
258 MAbs in the setting of continuously mutating SARS-Cov-2 when conducting conventional randomized
259 controlled clinical trials may not be practical. However, our study has several limitations: 1)
260 retrospective study design not allowing to rule residual confounding; 2) lack of symptom severity
261 assessment among patients (possibility of more symptomatic patients on the BEB MAb group vs.

262 asymptomatic patients on the control arm); 3) not measuring the impact of immunity through prior
263 COVID-19 infection(s); 4) not knowing patients' vaccination booster status (3rd or 4th booster); 5) lack of
264 specific SARS-Cov-2 Omicron subvariant genotype sampling; 6) not capturing patients may have received
265 Ritonavir-boosted nirmatrelvir (Paxlovid) and other approved therapies by healthcare providers outside
266 our healthcare system.

267 In conclusion, the BEB MAb use lacked efficacy in patients with SARS-CoV-2 Omicron subvariants in the
268 Banner Healthcare System (a large not-for-profit organization) in the Southwestern United States. Under
269 the light of the current study findings and an expectation of the majority of Omicron subvariants
270 becoming resistant, the continuing use of BEB MAb may no longer be justified. Continuing real-world
271 research from other large healthcare organizations in the different regions of the United States would
272 be needed to assess generalizability.

273

274 Acknowledgment: The authors thank to Chad Whelan, MD, Joshua Lee, MD, and Gordon Carr, MD, for
275 their support.

276

277 Conflict of Interest: The authors declared no conflict of interest related to this research. Dr. M Al-Obaidi
278 reported that he received an honorarium from Shionogi Inc. and La Jolla pharmaceuticals for serving in
279 their advisory board meetings.

280

281 Funding/ Support: None.

282 References:

- 283 1. Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, et al. Antibody evasion properties of SARS-CoV-2
284 Omicron sublineages. *Nature*. 2022;604(7906):553-6.
- 285 2. Takashita E, Yamayoshi S, Simon V, van Bakel H, Sordillo EM, Pekosz A, et al. Efficacy of
286 Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. *N Engl J Med*.
287 2022;387(5):468-70.
- 288 3. Bruel T, Hadjadj J, Maes P, Planas D, Seve A, Staropoli I, et al. Serum neutralization of SARS-CoV-
289 2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. *Nat Med*.
290 2022;28(6):1297-302.
- 291 4. US Food and Drug Administration. COVID-19 update: FDA authorizes new monoclonal antibody
292 for treatment of COVID-19 that retains activity against Omicron variant. Available at:
293 [https://www.fda.gov/news-events/
294 new-monoclonal-antibody-treatment-covid-19-retains](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fdaauthorizes-new-monoclonal-antibody-treatment-covid-19-retains). Accessed on November 11, 2022.
- 295 5. Gershengorn HB, Patel S, Ferreira T, Das S, Parekh DJ, Shukla B. The clinical effectiveness of
296 REGEN-COV in SARS-CoV-2 infection with Omicron versus Delta variants. *PLoS One*.
297 2022;17(12):e0278770.
- 298 6. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and
299 etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory
300 COVID-19. medRxiv. Preprint and has not been peer-reviewed. Available at doi:
301 <https://doi.org/10.1101/2022.03.10.22272100>.
- 302 7. McCreary EK, Kip KE, Collins K, Minnier TE, Snyder GM, Steiner A, et al. Evaluation of
303 Bebtelovimab for Treatment of Covid-19 During the SARS-CoV-2 Omicron Variant Era. *Open Forum*
304 *Infect Dis*. 2022;9(10):ofac517.
- 305 8. Razonable RR, O'Horo JC, Hanson SN, Arndt RF, Speicher LL, Seville TA, et al. Outcomes of
306 Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients
307 with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch. *J Infect Dis*. 2022.
- 308 9. CoVariants. Available at <https://covariants.org/>, accessed on 11/10/2022.
- 309 10. The Banner Health COVID-19 Treatment. Available at [https://www.bannerhealth.com/staying-
310 well/health-and-wellness/wellness/covid/treatment](https://www.bannerhealth.com/staying-well/health-and-wellness/wellness/covid/treatment), accessed on 11/10/2022.
- 311 11. Arizona State Immunization Information System [ASIIS], available at <https://asiis.azdhs.gov/>,
312 accessed on 11/12/2022.
- 313 12. Adjei S, Hong K, Molinari NM, Bull-Otterson L, Ajani UA, Gundlapalli AV, et al. Mortality Risk
314 Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic
315 Periods - United States, April 2020-June 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(37):1182-9.
- 316 13. Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape
317 antibodies elicited by Omicron infection. *Nature*. 2022;608(7923):593-602.
- 318 14. Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404
319 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. *Cell Rep*. 2022;39(7):110812.
- 320 15. Shertel T, Lange NW, Salerno DM, Hedvat J, Jennings DL, Choe JY, et al. Bebtelovimab for
321 Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. *Transplantation*.
322 2022;106(10):e463-e4.
- 323 16. Yetmar ZA, Beam E, O'Horo JC, Seville MT, Brumble L, Ganesh R, et al. Outcomes of
324 bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate
325 coronavirus disease 2019 during the Omicron epoch. *Transpl Infect Dis*. 2022;24(4):e13901.
- 326 17. The NIH COVID-19 Treatment Guidelines Panel's Statement on Omicron Subvariants, Pre-
327 Exposure Prophylaxis, and Therapeutic Management of Nonhospitalized Patients With COVID-19.

- 328 Available at: [https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-](https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/)
329 [subvariants/](https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-omicron-subvariants/). Accessed on November 20, 2022.
- 330 18. Food and Drug Administration. Fact sheet for healthcare providers: Emergency Use
331 Authorization for bebtelovimab. 2022. Available at: <https://www.fda.gov/media/156152/download>.
332 Accessed on November 20, 2022.
- 333 19. Cao Y, Jian F, Wang J, et al. Imprinted SARS-CoV-2 humoral immunity induces convergent
334 Omicron RBD evolution. bioRxiv. 2022;Preprint. Available at:
335 <https://www.biorxiv.org/content/10.1101/2022.09.15.507787v4>. Accessed on November 20, 2022.
- 336 20. FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region. Available at:
337 [https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region)
338 [authorized-any-us-region](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region), accessed on December 3, 2022.
- 339





Figure 1



Number at risk

Control	1091	1071	1061	924	689	449
Bebtelovimab mAb	1091	1072	1063	915	661	437

Figure 2